News

The patent relates to enteric coated formulations of crofelemer used to treat secretory diarrhea. The enteric coating allows crofelemer to pass through the stomach into the intestine where

This is the third IND candidate from Astex’s internal discovery and development programmes to be approved. Astex plans to begin clinical trials of AT13387 in cancer patients during

In the intent-to-treat cohort in the study after 90 days, the tested therapeutic dose of NX-1207 had a mean BPH (benign prostatic hyperplasia) symptom score improvement of 9.71

The agreement includes $123 million in upfront and potential development milestone payments from Kyowa to ArQule, of which ArQule previously received a $30 million cash licensing payment. The

Currently aimed at developing and manufacturing mammalian cell culture-based products, the expansion means Cook Pharmica also will offer formulation, filling and finishing services to customers. The facility will

Novo Nordisk continues to fully fund Neose’s development work for Factor VIII. The company is also working with Novo Nordisk under separate license agreements to develop long-acting, GlycoPEGylated

The newly licensed myokines include a novel secreted protein named NK102 which has demonstrated significant blood glucose reductions when administered to obese animals. Other licensed proteins include NK110

The primary objectives of the study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Safety assessments include measurement of

As part of the agreement BioWisdom will join the InforSense Open Workflow Partner Network. Michael Stapleton, chief business officer of BioWisdom, said: “SRS provides a specialist healthcare search